Tremfya (guselkumab) – J&J’s follow-up to blockbuster IL-12 and IL-23 inhibitor Stelara (ustekinumab) – has been approved in the US for moderate-to-severe plaque psoriasis since 2017.

Tremfya (guselkumab) is also the only drug in the class to achieve clinical remission and endoscopic response at one year with a fully subcutaneous treatment regimen, according to the drugmaker.

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...

Notable Innovative Medicine products include Carvykti, Darzalex, Tecvayli, Rybrevant, Talvey, and Tremfya. Meanwhile, it makes a variety of medical technology devices and products, including ...

Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.